Plus Therapeutics (PSTV on Nasdaq) is a U.S. clinical-stage pharmaceutical company, backed by talented executives and a nationwide network of scientists, engineers and physicians.
With a hybrid virtual drug development model, we are well-positioned to be capital efficient, enhance operational efficiencies, decrease costs, and accelerate product development. We are headquartered in Austin, Texas, with additional laboratories and state-of-the-art clean rooms in San Antonio, Texas in order to undertake key development, manufacturing, and preclinical activities..
Our location provides us with many strategic advantages, including proximity to world-class cancer institutions and researchers – as well as the ability to qualify and apply for funding through the Cancer Prevention and Research Institute of Texas (CPRIT).
A knowledgeable and effective team that marries the proper skills with a similar mindset.
A growing suite of innovative radiotherapeutic formulations and targeted delivery technologies.
The identification of logical clinical targets with a high likelihood of FDA approval and positive patient outcomes.
The rapid advancement of our drug candidates through the development cycle in a cost-effective manner.
A set of partners with supportive technologies that increase our chance of clinical and commercial success.
Our platform is built on novel formulations comprised of beta- and gamma-energy-emitting Rhenium radionuclides, novel radioisotope loading technology such as BMEDA chelation and nanoliposomes, and biodegradable microspheres. We leverage unique combinations of these components to develop our lead product candidates, rhenium (186Re) obisbemeda and 188RNL-BAM. They have the potential to deliver effective, elevated doses of radiation directly to complex tumors, while sparing healthy tissue.